Etanercept works for psoriasis patients after they lose response to adalimumab

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Patients with moderate-to-severe psoriasis who stopped responding to adalimumab (Humira) had a satisfactory response to etanercept (Enbrel) even if they had anti-adalimumab antibodies (ADA).
Why this matters
  • Some patients who take TNF inhibitor therapy lose response to them over time.
Study design
  • Phase 4, open-label, single-arm estimation study including 64 patients who had achieved static physician global assessment (sPGA) score of 0/1 on adalimumab but lost response.
  • Loss of response defined as sPGA ≥3 or loss of 50% improvement in Psoriasis Area and Severity Index (PASI 50).
  • Patients then received etanercept 50 mg twice a week for 12 wk and then 50 mg weekly for 12 wk.
  • ADA measured ...